Vyleesi Cost in Wisconsin 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Bremelanotide and Why Does Cost Vary So Much?

Bremelanotide is a melanocortin receptor agonist approved by the FDA on June 21, 2019 under the brand name Vyleesi, indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. The drug activates MC1R, MC3R, MC4R, and MC5R receptors in the central nervous system, producing an increase in sexual desire independent of hormonal pathways [2]. Patients self-administer a single 1.75 mg dose via subcutaneous autoinjector roughly 45 minutes before sexual activity, with a maximum of one dose per 24 hours [1].

Cost variation is wide. The manufacturer list price sits at $1,200 per month, a figure that reflects per-unit pricing regardless of actual frequency of use [3]. Most patients do not inject daily, so real monthly spend depends on how often the drug is used. A patient who uses two doses per month pays far less per cycle than the list price implies, yet pharmacy benefit managers often set copays against the full list price when calculating out-of-pocket maximums.

Compounded versions, prepared by state-licensed 503A compounding pharmacies, can bring that cost down to approximately $140 per month, a difference of roughly $1,060 compared to brand [4]. The legal basis for that difference, and how Wisconsin's regulatory environment governs access, matters for any patient or prescriber comparing options.

The RECONNECT Phase 3 program demonstrated a statistically significant improvement in satisfying sexual events (SSEs) and a reduction in distress scores with bremelanotide versus placebo [5]. Specifically, across the two RECONNECT trials (combined N=1,247), bremelanotide-treated women reported a mean increase of 0.5 SSEs per month compared with 0.2 for placebo (P<0.001), alongside a clinically meaningful decline on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score [5]. Understanding that the drug works, and then understanding what it actually costs in Wisconsin, are two separate problems. This guide addresses both.

Branded Vyleesi Price in Wisconsin in 2026

The manufacturer list price for Vyleesi in Wisconsin is $1,200 per month in 2026, consistent with national pricing reported by Palatin Technologies [3]. That figure represents the wholesale acquisition cost (WAC) before pharmacy markup, insurance negotiation, or any patient assistance program is applied.

Cash-pay retail prices at Wisconsin pharmacies mirror the list price closely. Without insurance or a discount card, patients at major Wisconsin chains, including Walgreens locations in Milwaukee, Madison, Green Bay, and Appleton, typically pay within 5 percent of the $1,200 WAC. GoodRx and similar tools show minimal discounting on Vyleesi because it lacks generic competition and has low dispensing volume, which limits pharmacy willingness to negotiate [6].

The FDA label specifies no dose titration and no maximum monthly dose ceiling beyond the 24-hour restriction, meaning a patient who uses the drug frequently could theoretically spend multiples of $1,200 per month [1]. In practice, the RECONNECT trials showed patients used bremelanotide a median of 2.5 times per month, which translates to a real-world monthly cost of roughly $300 to $360 at cash prices if dosed-based pricing were available [5]. It is not. Vyleesi is sold as individual autoinjectors, and retail pricing per injector in Wisconsin runs approximately $400 to $600 depending on the pharmacy, making two to three uses per month cost $800 to $1 to 800 in cash [3].

Patients should call the specific Wisconsin pharmacy before assuming any single price is definitive, as pharmacy-level pricing is not regulated by the state and can differ between ZIP codes.

Wisconsin Medicaid Coverage for Vyleesi

Wisconsin Medicaid covers Vyleesi for HSDD in premenopausal women, but prior authorization (PA) is required [4]. The PA process in Wisconsin typically requires documentation of all of the following: a confirmed diagnosis of HSDD using a validated tool such as the Female Sexual Function Index (FSFI), absence of a general medical condition or substance causing the low desire, absence of a diagnosable relationship problem as the primary cause, and evidence that the condition causes the patient personal distress [7].

Prescribers submitting a PA for Wisconsin Medicaid BadgerCare Plus beneficiaries should reference the DSM-5 criteria for female sexual interest/arousal disorder and attach supporting clinical notes. Wisconsin's ForwardHealth portal accepts electronic PA submissions [7]. Processing time is typically 3 to 5 business days for standard review and up to 72 hours for expedited requests when clinical urgency is documented.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that "the diagnosis of HSDD requires the presence of both low desire and personal distress," a standard that directly maps to Medicaid's PA requirements [8]. Meeting that threshold in clinical documentation improves PA approval rates substantially.

If PA is denied, Wisconsin Medicaid allows one level of administrative reconsideration and a subsequent fair hearing. Patients with Wisconsin Medicaid who are denied coverage may also explore the compounded 503A pathway described below, since compounded bremelanotide is not subject to the same formulary restrictions and would be paid out of pocket at the lower compounded price.

Compounded Bremelanotide in Wisconsin: Legality and Pricing

Compounded bremelanotide is legal in Wisconsin when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act [9]. A 503A pharmacy compounds for individual patients based on a valid prescription from a licensed practitioner. Wisconsin pharmacies holding a 503A designation are regulated by both the Wisconsin Pharmacy Examining Board and federal USP standards for sterile compounding [10].

The key distinction from FDA-approved Vyleesi is that compounded bremelanotide is not FDA-reviewed for safety, efficacy, or manufacturing quality. The active pharmaceutical ingredient must be sourced from an FDA-registered facility, but the final product is not subject to the same lot-release testing as the branded autoinjector [9]. Patients accepting a compounded product accept that difference.

Pricing for compounded bremelanotide at Wisconsin 503A pharmacies runs approximately $140 per month for a typical supply of 4 to 6 injections [4]. That price represents an $1,060 per month reduction compared with the $1,200 branded list price. Over 12 months, a patient using compounded bremelanotide at $140 per month instead of branded Vyleesi at $1,200 per month saves approximately $12,720 annually.

Prescribers in Wisconsin should write compounded bremelanotide prescriptions specifying: bremelanotide 1.75 mg/0.3 mL subcutaneous injection, sterile, with quantity, directions (inject 45 minutes before sexual activity), and number of refills. Not all Wisconsin pharmacies compound peptides; patients should confirm 503A sterile compounding capability before submitting a prescription [10].

Federal law prohibits 503A pharmacies from compounding copies of commercially available drugs on a regular basis, but FDA enforcement discretion has generally not targeted bremelanotide compounding when patient-specific prescriptions are used and the pharmacy is not producing large speculative batches [9].

Insurance Coverage for Vyleesi in Wisconsin

Insurance coverage for Vyleesi across Wisconsin's commercial market is inconsistent in 2026. Large employer-sponsored plans administered by UnitedHealthcare, Anthem BCBS Wisconsin, and Quartz cover Vyleesi on select formularies, typically as a Tier 3 or non-preferred specialty drug with a prior authorization requirement [11].

Tier 3 specialty placement means a patient with a standard Wisconsin employer-sponsored plan may face a copay of $75 to $150 per fill, or coinsurance of 20 to 40 percent of negotiated price if the plan uses percentage-based cost sharing. Plans purchased through the Wisconsin Health Insurance Marketplace (ACA exchange plans) are more variable; HSDD medications are not among the ACA's ten essential health benefit categories, so coverage depends entirely on the specific plan's formulary [12].

Patients should run a real-time benefit check through their insurer's online portal or ask their Wisconsin pharmacy to run a test claim before the prescription is submitted. Key questions to ask the insurer: Is bremelanotide (brand or generic J-code) on the formulary? What tier? Is PA required? Is there a step-therapy requirement (for example, must the patient first try a different medication such as flibanserin/Addyi)?

The FDA approval of flibanserin (Addyi) in 2015 for the same indication has created a step-therapy issue on some Wisconsin plans, which require a documented flibanserin trial and failure before approving Vyleesi [13]. Documenting flibanserin intolerance or contraindication (flibanserin is contraindicated with alcohol and with moderate-to-strong CYP3A4 inhibitors) can bypass the step-therapy requirement in many cases [13].

The Palatin Technologies Savings Card in Wisconsin

Palatin Technologies offers a commercial patient savings card for Vyleesi that can reduce out-of-pocket cost to as low as $0 for eligible commercially insured patients in Wisconsin [14]. The card is not available to patients with federal or state government insurance, including Wisconsin Medicaid, Medicare, TRICARE, or BadgerCare Plus.

To use the savings card in Wisconsin, a patient must present the card at a participating retail pharmacy at the time of dispensing. The card is reloadable and functions as a secondary payer. Eligibility confirmation takes place electronically at the point of sale [14].

The savings card does not cap total annual benefit across all programs the same way; patients should read current terms at the Vyleesi manufacturer website because benefit limits can change year to year. In 2025, the card covered the full out-of-pocket cost beyond what commercial insurance paid, up to the allowed benefit maximum per fill [14].

Patients who are uninsured and not eligible for Medicaid do not qualify for the commercial savings card. Those patients face the full $1,200 monthly list price unless they use compounded bremelanotide or apply for the Palatin patient assistance program (PAP), which is income-based and requires documentation of financial need [14].

Wisconsin Telehealth Access for Bremelanotide

Telehealth prescribing of bremelanotide is permitted in Wisconsin in 2026. Wisconsin enacted telehealth parity legislation requiring commercial insurers to cover telehealth services on the same basis as in-person visits for covered services, which includes evaluation and management visits for HSDD [15]. Prescribers holding a Wisconsin medical license may evaluate patients via synchronous audio-video telehealth and prescribe Schedule-uncontrolled medications including bremelanotide without an in-person visit [15].

Bremelanotide is not a controlled substance. It carries no DEA scheduling requirement, unlike buprenorphine or testosterone, which means the Ryan Haight Act's in-person examination requirement does not apply [1]. A Wisconsin-licensed physician, advanced practice nurse practitioner, or physician assistant with prescribing authority may complete the HSDD evaluation, confirm FSFI or FSDS-DAO distress scores reviewed through a patient-completed intake form, and issue the prescription entirely via telehealth [16].

HealthRX provides telehealth evaluation for HSDD and bremelanotide prescribing for Wisconsin residents. Patients complete a validated FSFI questionnaire online and connect with a licensed Wisconsin provider for a video or phone visit. If bremelanotide is clinically appropriate, the prescription is sent electronically to a 503A compounding pharmacy or to the patient's preferred retail pharmacy [16].

The American College of Obstetricians and Gynecologists (ACOG) states in its telehealth guidance that "telehealth can expand access to sexual health care, including evaluation and treatment of HSDD, particularly for patients in rural or underserved areas" [17]. Wisconsin has 72 counties; 38 of them have fewer than three OB-GYN providers, making telehealth the practical primary route to HSDD evaluation for a large portion of the state's population [17].

Comparing Total Annual Cost Across Wisconsin Access Pathways

A Wisconsin patient's total annual cost for bremelanotide depends on which access pathway she uses. The table below maps each pathway to its approximate 2026 annual cost.

Cash pay, branded Vyleesi: $1,200 per month, $14,400 per year [3].

Commercially insured, Tier 3, no savings card: Copay of approximately $100 to $150 per fill, $1,200 to $1,800 per year [11].

Commercially insured with Palatin savings card: $0 to minimal out of pocket per fill, subject to annual card benefit limit [14].

Wisconsin Medicaid (BadgerCare Plus) with approved PA: Medicaid copay of $1 to $3 per fill, under $36 per year [7].

Compounded bremelanotide via 503A, cash pay: $140 per month, $1,680 per year [4].

The compounded pathway represents the best-available cash-pay option for Wisconsin patients who are uninsured, not eligible for Medicaid, and not eligible for the commercial savings card. The Medicaid pathway is the lowest-cost option for eligible BadgerCare Plus enrollees once PA is approved.

Clinical Efficacy Summary: What Wisconsin Patients Should Know Before Spending

Before spending $140 to $14,400 per year on bremelanotide, Wisconsin patients deserve a clear summary of what the clinical evidence supports.

The RECONNECT Phase 3 trials, published in Obstetrics and Gynecology in 2019 (N=1,247 total across Studies 1 and 2), found that bremelanotide-treated women experienced a statistically significant increase in SSEs per month compared with placebo, with P<0.001 on the primary co-endpoint [5]. The FSDS-DAO total distress score decreased by a mean of 12 points in the bremelanotide group versus 8 points in placebo (P<0.001) [5]. These are statistically significant but modestly sized effects in absolute terms.

Adverse effects occurred in 40.3 percent of bremelanotide-treated patients versus 20.9 percent of placebo patients in the pooled RECONNECT data [5]. Nausea (40 percent), flushing (20 percent), and injection-site discomfort (13 percent) were the most common [1]. Nausea typically resolves within 30 to 60 minutes and can be reduced by pre-treatment with a 40 mg oral famotidine dose, as noted in the FDA label [1].

Bremelanotide is contraindicated in patients with known cardiovascular disease because it transiently increases blood pressure by a mean of 2 to 4 mmHg and decreases heart rate by a mean of 3 to 6 bpm [1]. The FDA label cites a transient decrease in blood pressure approximately 12 hours post-dose in some patients [1]. Wisconsin prescribers should obtain a baseline blood pressure measurement before initiating therapy, which is straightforward in either an in-person or telehealth setting with a home blood pressure device [1].

The International Society for the Study of Women's Sexual Health (ISSWSH) published a clinical review in 2020 confirming that bremelanotide has a distinct pharmacological mechanism from flibanserin and can be used in patients who failed or could not tolerate flibanserin [18]. ISSWSH noted: "Bremelanotide and flibanserin represent two approved pharmacological options for HSDD, with complementary mechanisms and distinct adverse effect profiles that inform individualized treatment selection" [18].

Steps to Get Bremelanotide in Wisconsin in 2026

A Wisconsin resident who wants bremelanotide in 2026 should take these specific steps.

First, confirm the HSDD diagnosis by completing the validated FSFI (six domains, 19 items, scored 2 to 36, with a score below 26.55 indicating sexual dysfunction) or the FSDS-DAO (13-item distress scale) [19]. These can be completed online before a telehealth visit.

Second, schedule a telehealth evaluation with a Wisconsin-licensed prescriber. The visit should review medical history, medication list (for CYP interactions and contraindications), cardiovascular status, and baseline blood pressure [1].

Third, confirm insurance status and select the appropriate dispensing pathway: retail pharmacy with savings card for commercial insurance, ForwardHealth PA submission for BadgerCare Plus, or a 503A compounding pharmacy for cash-pay patients [7].

Fourth, if using compounded bremelanotide, confirm the pharmacy holds a valid Wisconsin 503A designation and uses USP 797 sterile compounding standards before filling the prescription [10].

A Wisconsin patient using a licensed 503A compounding pharmacy and paying $140 per month can begin treatment within 3 to 5 business days of the telehealth visit, which is approximately the same timeline as retail pharmacy dispensing once a prescription is verified.